Table 1.

Summary of Studies Evaluating HIV-Associated Distal Sensory Polyneuropathy (DSPN)

Abstract No. Authors	Location	Sample Size	Prevalence	Correlates
Abstract 461 Ellis et al	United States	1539	57% ≥ 1 sign 28% ≥ 2 signs 38% symptomatic	Older age, lower CD4+ nadir, history of d-drug use, current antiretroviral therapy use, history of opiate use
Abstract 462 Evans et al	United States	2135	30% ≥ 1 sign at 48 weeks 41% ≥ 1 sign at 8 years 5% symptomatic	Older age, history of d-drug use, higher pre–antiretroviral therapy plasma viral load, lower pre–antiretroviral therapy CD4+ count
Abstract 160 Canter et al	United States	230	Up to 56% DSPN	Mitochondrial haplogroup, older age, d-drug use
Abstract 161 Cherry et al	Australia, Indonesia, Malaysia	37	Up to 66% DSPN	Taller height, older age, d-drug use
Abstract 463 Ances et al	United States	130	55% DSPN	Fasting hypertriglyceridemia, diabetes mellitus
Abstract 466 Cherry et al	Australia, Indonesia, Malaysia, United States	503	Up to 62% DSPN	Varied by site (Kuala Lumpur, 19%; Baltimore, 62%), not hepatitis C virus infection

D-drug indicates the dideoxynucleoside analogue–containing drugs stavudine and didanosine.